Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DNX-2440 |
| Synonyms | |
| Therapy Description |
DNX-2440 is the replication component of an engineered adenovirus that expresses human OX40 ligand, which may stimulate anti-tumor immune response (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DNX-2440 | DNX 2440|DNX2440 | DNX-2440 is the replication component of an engineered adenovirus that expresses human OX40 ligand, which may stimulate anti-tumor immune response (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03714334 | Phase I | DNX-2440 | DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | Terminated | ESP | 0 |
| NCT04714983 | Phase I | DNX-2440 | DNX-2440 for Resectable Colorectal Liver Metastasis | Suspended | USA | 0 |